Stuart Milstein appointed Chief Platform Officer, bringing decades of experience in oligonucleotide drug development to underpin Aerska’s platform R&DLisa Taylor Ash joins Board of Directors, ...

A new possibility for managing cardiovascular disease through RNA interference (RNAi) gene therapies. As cardiovascular diseases continue to be the leading cause of death globally, this technology ...

SAN FRANCISCO (AP) _ The biotechnology field is littered with the debris of would-be miracle cures. These days, the buzz is building around a technology called ``RNA interference,'' whose legions of ...

LONDON, Feb 26 (Reuters) - Britain's Ark Therapeutics said on Thursday it had filed a patent application for a new genetic technique that represents an advance in so-called RNA interference technology ...

Ionis is a leader in RNA-based therapies, and its spinal muscular atrophy drug Spinraza, marketed by partner Biogen, is the first RNA-based therapy to achieve blockbuster status. The firm's antisense ...